Effects of chronic antidepressant treatments on serotonin transporter function, density, and mRNA level
- PMID: 10575045
- PMCID: PMC6782424
- DOI: 10.1523/JNEUROSCI.19-23-10494.1999
Effects of chronic antidepressant treatments on serotonin transporter function, density, and mRNA level
Abstract
To investigate functional changes in the brain serotonin transporter (SERT) after chronic antidepressant treatment, several techniques were used to assess SERT activity, density, or its mRNA content. Rats were treated by osmotic minipump for 21 d with the selective serotonin reuptake inhibitors (SSRIs) paroxetine or sertraline, the selective norepinephrine reuptake inhibitor desipramine (DMI), or the monoamine oxidase inhibitor phenelzine. High-speed in vivo electrochemical recordings were used to assess the ability of the SSRI fluvoxamine to modulate the clearance of locally applied serotonin in the CA3 region of hippocampus in drug- or vehicle-treated rats. Fluvoxamine decreased the clearance of serotonin in rats treated with vehicle, DMI, or phenelzine but had no effect on the clearance of serotonin in SSRI-treated rats. SERT density in the CA3 region of the hippocampus of the same rats, assessed by quantitative autoradiography with tritiated cyanoimipramine ([(3)H]CN-IMI), was decreased by 80-90% in SSRI-treated rats but not in those treated with phenelzine or DMI. The serotonin content of the hippocampus was unaffected by paroxetine or sertraline treatment, ruling out neurotoxicity as a possible explanation for the SSRI-induced decrease in SERT binding and alteration in 5-HT clearance. Levels of mRNA for the SERT in the raphe nucleus were also unaltered by chronic paroxetine treatment. Based on these results, it appears that the SERT is downregulated by chronic administration of SSRIs but not other types of antidepressants; furthermore, the downregulation is not caused by decreases in SERT gene expression.
Figures







Similar articles
-
Serotonin clearance in vivo is altered to a greater extent by antidepressant-induced downregulation of the serotonin transporter than by acute blockade of this transporter.J Neurosci. 2002 Aug 1;22(15):6766-72. doi: 10.1523/JNEUROSCI.22-15-06766.2002. J Neurosci. 2002. PMID: 12151556 Free PMC article.
-
Association of changes in norepinephrine and serotonin transporter expression with the long-term behavioral effects of antidepressant drugs.Neuropsychopharmacology. 2009 May;34(6):1467-81. doi: 10.1038/npp.2008.183. Epub 2008 Oct 15. Neuropsychopharmacology. 2009. PMID: 18923402 Free PMC article.
-
Exaggerated effect of fluvoxamine in heterozygote serotonin transporter knockout mice.J Neurochem. 2003 Jul;86(1):210-9. doi: 10.1046/j.1471-4159.2003.01836.x. J Neurochem. 2003. PMID: 12807440
-
Neuropharmacology of paroxetine.Psychopharmacol Bull. 2003 Spring;37 Suppl 1:8-18. Psychopharmacol Bull. 2003. PMID: 14566196 Review.
-
Pharmacologic differences among the SSRIs: focus on monoamine transporters and the HPA axis.CNS Spectr. 2004 Jun;9(6 Suppl 4):23-31. doi: 10.1017/s1092852900025475. CNS Spectr. 2004. PMID: 15181382 Review.
Cited by
-
Chronic Ritalin administration during adulthood increases serotonin pool in rat medial frontal cortex.Iran Biomed J. 2013;17(3):134-9. doi: 10.6091/ibj.1173.2013. Iran Biomed J. 2013. PMID: 23748891 Free PMC article.
-
Comparison of ΔFosB immunoreactivity induced by vagal nerve stimulation with that caused by pharmacologically diverse antidepressants.J Pharmacol Exp Ther. 2012 May;341(2):317-25. doi: 10.1124/jpet.111.188953. Epub 2012 Jan 27. J Pharmacol Exp Ther. 2012. PMID: 22286499 Free PMC article.
-
The effect of citalopram hydrobromide on 5-HT2A receptors in the impulsive-aggressive dog, as measured with 123I-5-I-R91150 SPECT.Eur J Nucl Med Mol Imaging. 2005 Jun;32(6):708-16. doi: 10.1007/s00259-005-1772-5. Eur J Nucl Med Mol Imaging. 2005. PMID: 15739093
-
Serotonin Receptor and Transporter Endocytosis Is an Important Factor in the Cellular Basis of Depression and Anxiety.Front Cell Neurosci. 2022 Feb 24;15:804592. doi: 10.3389/fncel.2021.804592. eCollection 2021. Front Cell Neurosci. 2022. PMID: 35280519 Free PMC article.
-
The selective norepinephrine reuptake inhibitor antidepressant reboxetine: pharmacological and clinical profile.CNS Drug Rev. 2004 Spring;10(1):23-44. doi: 10.1111/j.1527-3458.2004.tb00002.x. CNS Drug Rev. 2004. PMID: 14978512 Free PMC article. Review.
References
-
- Auerbach SB, Hjorth S. Effect of chronic administration of the selective serotonin (5-HT) uptake inhibitors citalopram on extracellular 5-HT and apparent autoreceptor sensitivity in rat forebrain in vivo. Naunyn Schmiedebergs Arch Pharmacol. 1995;352:597–606. - PubMed
-
- Blakely RD, Ramamoorthy S, Qian Y, Schroeter S, Bradley CC. Regulation of antidepressant-sensitive serotonin transporters. In: Reith MEA, editor. Neurotransmitter transporters. Structure, function and regulation. Humana; Totowa, NJ: 1997. pp. 29–72.
-
- Brunello N, Riva M, Volterra A, Racagni G. Effect of some tricyclic and nontricyclic antidepressants on [3H]imipramine binding and serotonin uptake in rat cerebral cortex after prolonged treatment. Fundam Clin Pharmacol. 1987;1:327–333. - PubMed
-
- Burnet PWJ, Michelson D, Smith MA, Gold PW, Sternberg EM. The effect of chronic imipramine administration on the densities of 5-HT1A and 5-HT2 receptor and the abundancies of 5-HT receptor and transporter mRNA in the cortex, hippocampus and dorsal raphe of tree strain of rats. Brain Res. 1994;638:311–324. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous